Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep910 | Reproductive and Developmental Endocrinology | ECE2022

Developmental programming by maternal androgen excess is mediated by androgen receptor pathways

Lu Haojiang , Li Congru , Pei Yu , Eriksson Gustaw , Pui Han-Pin , Risal Sanjiv , Torstensson Sara , Ascani Angelo , Lindgren Eva , Ohlsson Claes , Benrick Anna , Stener-Victorin Elisabet , Deng Qiaolin

Introduction: The hyperandrogenic in utero environment in pregnant women with polycystic ovary syndrome (PCOS) can affect embryo development and impair offspring health at adult age. Moreover, long term hyperandrogenic exposure also leads to unfavored changes to the mothers’ reproductive physiology, leading to miscarriage, preterm delivery, and perinatal mortality. The underlying mechanism(s) of pregnancy complications associated with PCOS and the consequence of ...

ea0084ps3-12-107 | Graves’ Disease 2 and Orbitopathy | ETA2022

Macrophage-orbital fibroblasts interaction in context of hypoxic signaling for inflammatory processes during graves’ orbitopathy

Gortz Gina-Eva , Eckstein Anja , Jesenek Christoph , Horstmann Mareike , Philipp Svenja , Bruderek Kirsten , Oeverhaus Michael , Daser Anke , Bechrakis Nikolaos , Brandau Sven , Berchner-Pfannschmidt Utta

Introduction: The inflammatory eye disease Graves’ orbitopathy (GO) is the main complication of Graves’ disease in patients. In previous studies we have shown that hypoxia and HIF-1 dependent pathways could play an important role in the pathogenic process of GO. Hypoxia is known to attract inflammatory cells and therefore maintains inflammation and recruitment of immune cells like macrophages (MQ). However, few is known about the specific contribution of MQ to the pr...

ea0090ep675 | Pituitary and Neuroendocrinology | ECE2023

Metabolic and surgical outcomes of adult patients with craniopharyngiomapatients undergoing extended transsphenoidal surgery (ETS) at a referral center

Pinar Gutierrez Ana , Dios Elena , Venegas-Moreno Eva , Remon Pablo , Oulad Ahmed Bothayna , Kaen Ariel , Cardenas Eugenio , Fajardo Elena , Cano Gonzales David , Soto-Moreno Alfonso

Objectives: To describe the metabolic and surgical outcomes of adult patients with craniopharyngioma undergoing extended transsphenoidal surgery (ETS). Secondary: to compare surgical outcomes with patients undergoing conventional transcranial surgery (CTS).Methods: Retrospective observational study. Adult patients with craniopharyngiomas undergoing ETS between 2015 and 2020 were included. Descriptive analysis was performed by obtaining median and quartil...

ea0067o46 | Oral Presentations | EYES2019

Effect of treatment with Cinacalcet on TBS and BMD in patients with chronic renal failure with secondary hyperparathyroidism in hemodialysis

Reyes Laura Mola , Maria Soledad Librizzi , Martinez Eduardo Hernandez , Herrero Eva Merida , Cuellar Hernando Trujillo , Arriscado Cristina Martin , Carranza Federico Hawkins

Background: Fractures are frequent in patients with chronic renal failure (CRF) with secondary hyperparathyroidism (SHPT) undergoing hemodialysis. Cinacalcet (CT) is a drug used in the reduction of hypercalcemia in these patients that acts through the lintel calcium sensor in the parathyroid gland. Recently, it has been pointed out that CT can reduce fractures in these patients by unknown mechanisms (EVOLVE Trials 2015).Objectives: To evaluate the effect...

ea0066p73 | Pituitary | BSPED2019

Three novel Growth Hormone Receptor (GHR) splicing mutations causing a spectrum of Growth Hormone Insensitivity

Cottrell Emily , Maharaj Avinaash , Ladha Tasneem , Chatterjee Sumana , Grandone Anna , Cirillo Grazia , del Giudice Emanuele Miraglia , Kostalova Ludmila , Vitariusova Eva , Hwa Vivian , Metherell Louise A , Storr Helen L

Introduction: Growth Hormone Insensitivity (GHI) is characterised by a triad of short stature (SS), IGF-1 deficiency and normal/high GH levels. ‘Classical’ GHI due to homozygous exonic GHR mutations results in extreme SS with dysmorphic and metabolic abnormalities. Heterozygous exon 9 GHR mutations are rare and exert dominant negative effects due to impairment of GHR dimerization/downstream signalling associated with a milder GHI phenotype. Only sev...

ea0064014 | No deleterious effect of pretreatment with everolimus and/or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT | BES2019

No deleterious effect of pretreatment with everolimus and/or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT

Eva Medaer , Chris Verslype , Cutsem Eric Van , Dekervel Jeroen , Clement Paul , Nackaerts Kristiaan , Bex Marie , Gheysens Olivier , Goffin Karolien , Jentjens Sander , Laere Koen Van , Deroose Christophe M

Background: Treatment of neuro-endocrine tumors (NETs) is often challenging, given the heterogeneity of primary tumor sites, the individual disease complexity and the variety of treatment options. If patients are progressive during first-line treatment with somatostatin analogues (SSA), peptide receptor radionuclide therapy (PRRT) is a validated treatment for somatostatin receptor overexpressing neuroendocrine tumors. The NETTER-1 trial has demonstrated a pronounced positive e...

ea0063oc2.4 | Diabetes 1 | ECE2019

Empagliflozin attenuates the progression of atherosclerosis in APO-E knockout mice

Dimitriadis Georgios K , Nasiri-Ansari Narjes , Agrogannis Georgios , Nikiteas Nikolaos , Kostakis Ioannis D , Kaltsas Gregory , Papavassiliou Athanasios G , Kassi Eva , Randeva Harpal S

Background: Sodium glucose co-transporter 2 inhibitors reduce the incidence of cardiovascular events in patients with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with empagliflozin on biochemical and immunohistochemical markers related to atherosclerosis development in apolipoprotein E knockout [Apo-E(−/−)] mice.Methods: At the ag...

ea0063oc3.5 | Cushing's and acromegaly | ECE2019

T2-signal intensity, SST receptor expression and first-generation somatostatin analogues efficacy predict hormone and tumor responses to pasireotide in acromegaly

Coopmans Eva C , Schneiders Joppe J , El-Sayed Nour , Muhammad Ammar , Hofland Leo J , Petrossians Patrick , van der Lely Aart. J , JCMM Neggers Sebastian

Background: Previous studies indicate that PAS-LAR can achieve control of insulin-like growth factor I (IGF-I) levels and may reduce tumor size, however a subset of acromegaly patients responds poorly. T2-signal intensity, somatostatin receptor (SST) subtype 2 and 5 expression, and the response to first-generation somatostatin receptor ligands (SRLs) are recognized predictors of therapy response. Valid prediction of the response to PAS-LAR can alter treatment stratification.</...

ea0063gp40 | Metabolic Syndrome and Hypoglycaemia | ECE2019

Long-term administration of Empagliflozin may promote hepatic and renal lipid accumulation, and inflammation in the APOE knockout model

Tsara Anna , Nasiri-Ansari Narjes , Dimitriadis Georgios K , Theocharis Stamatis , Karapanagioti1 Angeliki , Danas Eougken , Papavassiliou Athanasios G , Randeva Harpal S , Kassi Eva

Introduction: Metabolic disorders characterized by insulin resistance/hyperinsulinemia, such as metabolic syndrome and T2DM, are associated with Non-Alcoholic Fatty Liver Disease (NAFLD). SGLT-2i reduce reabsorption of glucose from the kidneys thereby promoting glucosuria, while their beneficial effects on insulin resistance have been recently recognized. In this study, we aimed to investigate the effect of Empagliflozin, in de novo triglyceride synthesis and beta-oxi...

ea0063gp173 | Obesity (1) | ECE2019

Excellent tumor response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma

Coopmans Eva , van Meyel Sebastiaan , Pieterman Kay , van Ipenburg Jolique , Hofland Leo , Donga Esther , Daly Adrian , Beckers Albert , van der Lely Aart-Jan , Neggers Sebastian

Background: Prolactinomas are the most frequent secreting pituitary adenomas encountered in the clinical setting. Cabergoline is considered the mainstay medical treatment and transsphenoidal surgery (TSS) is recommended for patients that are medically resistant to dopamine agonist therapy. Resistance to dopamine agonists is commonly defined as failure to normalize prolactin and less than 50% decrease in tumor diameter at a maximal labeled dose of 2.0 mg/week. Pasireotide LAR (...